Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 08:43 ET | Source: CTD Holdings, Inc.

CTD Holdings Engages Torreya Capital as Strategic Advisor

ALACHUA, Fla., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
November 08, 2018 15:07 ET | Source: CTD Holdings, Inc.

CTD Announces Partnership with Synteract to support the Extension Protocol for its Phase I Clinical Trial in the United States

ALACHUA, Fla., Nov. 08, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
October 29, 2018 18:49 ET | Source: CTD Holdings, Inc.

CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease

ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with...
October 18, 2018 16:31 ET | Source: CTD Holdings, Inc.

CTD Holdings Posts Recording of its Webinar on US Clinical Trial

Webinar recording is on the Company website ALACHUA, Fla., Oct. 18, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops...
October 15, 2018 08:00 ET | Source: CTD Holdings, Inc.

CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™

Company expects to provide its drug to new patients in early 2019 ALACHUA, Fla., Oct. 15, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that...
October 11, 2018 12:57 ET | Source: CTD Holdings, Inc.

CTD Holdings to Host Webinar on its Phase I Clinical Trial for Niemann-Pick Disease Type C

ALACHUA, Fla., Oct. 11, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of...
October 09, 2018 12:03 ET | Source: CTD Holdings, Inc.

CTD Holdings to Present at BioFlorida Conference with update on Clinical Program Using Cyclodextrins to treat diseases with Unmet Medical Needs

ALACHUA, Fla., Oct. 09, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease...
October 05, 2018 08:00 ET | Source: CTD Holdings, Inc.

CTD Holdings Establishes Second Clinical Trial Site for US Phase I Clinical Study of Trappsol® Cyclo™ for Treatment of Niemann-Pick Disease Type C

Patients to be Enrolled at Atlantic Health System’s Morristown Medical Center, Morristown, New Jersey ALACHUA, Fla., Oct. 05, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical...
October 03, 2018 08:00 ET | Source: CTD Holdings, Inc.

CTD announces encouraging top-line data from two ongoing clinical trials of Trappsol® Cyclo™ administered intravenously in Niemann Pick Disease Type C (NPC)

ALACHUA, Fla., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of...
September 13, 2018 10:56 ET | Source: CTD Holdings, Inc.

CTD Holdings to Present at UK Annual Conference for NPC Patients, Families, and Health Professionals

Conference Brings the NPC community together for scientific exchanges and information sharing with NPC families ALACHUA, Fla., Sept. 13, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH),...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right